Investigators of the CEMI-LUNG study (NCT05363319) enrolled an unselected, real-world population of more than 200 patients ...

A biologics license application (BLA) for etentamig (ABBV-383) has been submitted to the FDA for the treatment of adults with ...

Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

The investigators concluded that AZUR-1 “demonstrates sustained clinical complete responses after dostarlimab monotherapy in ...

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used ...

Translating laboratory discoveries into clinical benefit for patients with breast cancer increasingly depends on combining ...

A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

The next-generation KRAS G12C inhibitor divarasib significantly prolonged progression-free survival (PFS) and overall ...

Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point. Although the phase 2 EVITA trial ...

Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma ...